Carregando empresa
Just reported
Q3 2026 results
From Hims & Hers Health's results release of 9 de novembro de 2026; its quarterly report has since been filed.
Revenue
Actual
US$ 890,4M
+49% y/y
+18% q/qGuided
US$ 890M
midpoint
Within guide0,0%EPS, GAAP
Actual
-US$ 0,14
Guided
—
No guide given
Operating income, GAAP
Actual
-US$ 66,1M
Guided
—
No guide given
Company outlook
Q4 2026
- RevenueUS$ 875M – US$ 895M+43% y/y First given
Full year 2026
- RevenueUS$ 3,13B – US$ 3,15B+34% y/y Lowered -1,9%
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Hims & Hers Health is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Drug Manufacturers Specialty and Generic
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company LimitedUS$ 33,5BA
NBIXNeurocrine Biosciences, Inc.US$ 17,6BA+
ELANElanco Animal Health IncorporatedUS$ 13,2BA
KNSAKiniksa Pharmaceuticals International, plcUS$ 8,1BA+
LQDALiquidia CorporationUS$ 5BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 de out. de 2026CBGraded C, now B
MCKMckesson Corporation4 de nov. de 2026BAGraded B, now A
CVSCVS Health Corp4 de nov. de 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 de nov. de 2026BAGraded B, now A
BIIBBiogen Inc.28 de out. de 2026BAGraded B, now A
Como ganha dinheiro
- Sales to customers in the United States87%
- Sales to customers outside the United States13%
As participações na receita são estimativas para quarter ended March 31, 2026, não números de um relatório oficial.
Concorre com
O que vende5
Prescription treatments
Medicines prescribed by clinicians for conditions including sexual health, hair loss, hormone health, weight loss, skin conditions, and mental health. Prescriptions may be filled by company-owned or partner pharmacies.
Weight-loss care and medicines
Weight-loss medicines, including access to branded medicines and, on a limited scale, compounded medicines, with a membership that can include ongoing clinician support.
Non-prescription products
Products such as skin care, hair care, sexual wellness products, cosmetics, and supplements, sold under Hims & Hers or co-branded with manufacturers.
Mostrar mais 2
Laboratory testing
Testing services that measure health markers and provide results to support health assessments and follow-up care with clinicians.
Telehealth consultations and follow-up care
Remote consultations with licensed healthcare professionals, who assess customers and may prescribe medication or provide ongoing care.
Quem compra3
- Consumers who buy prescription treatments and related care directly through Hims & Hers websites and apps; many choose recurring subscriptions and are billed when products ship or services are provided.
- Consumers who make one-time purchases through the websites, apps, or retail stores.
- Retail partners that buy or sell Hims & Hers non-prescription products in stores and on third-party websites.
Em que se apoia e o que pode quebrá-lo
Do que o negócio depende
- 1In the United States, clinical care depends on contractual relationships with independent affiliated medical groups, which retain control over medical decisions.
- 2Fulfilling prescriptions depends on licensed company-owned and partner pharmacies, product manufacturers, and suppliers.
- 3The business depends on access to the internet, cloud and payment providers, and systems that handle sensitive customer health information.
- 4Selling and fulfilling medicines, compounded drugs, and laboratory tests depends on healthcare, pharmacy, product-safety, and privacy rules in each market.
O que pode dar errado
- 1Regulators may restrict compounded medicines, including weight-loss drugs. The company received warning letters concerning promotion of compounded products, and the United States Food and Drug Administration said it intended to restrict certain ingredients for mass-marketed compounded drugs.
- 2Changes in telehealth and medical-practice rules could disrupt the company’s arrangements with affiliated medical groups or limit how clinicians assess patients and prescribe medicines.
- 3A data breach or failure to comply with changing privacy laws could expose sensitive health information, trigger penalties or lawsuits, and damage customer trust.
Demonstrações financeiras completas →
Sobre a Hims & Hers Health, Inc.
Customers use Hims & Hers websites and apps to find treatments, answer health questions, and connect with licensed healthcare professionals. When appropriate, clinicians prescribe medication, which Hims & Hers or other licensed pharmacies ship to customers; customers can also buy non-prescription products and laboratory testing. In the United States, independent medical groups make clinical decisions, while Hims & Hers provides administrative and technology services. It had 2.891 million subscribers (June 30, 2026, high), meaning customers with recurring billing; monthly revenue per average subscriber was $92 (three months ended June 30, 2026, high), a measure that also includes revenue from one-time purchases.
- Sede
- San Francisco, California
- Fundada em
- 2017
- Funcionários
- 2,442 (December 31, 2025, high)
- Listada em
- NYSE
- Fim do exercício
- December 31
Construído a partir dos próprios documentos de Hims & Hers Health, Inc. entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.
